Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ares-Serono Initiates Rebif v. Avonex Trial, May Beat Exclusivity Clock

Executive Summary

Ares-Serono has initiated a 600-patient trial to test the efficacy of Rebif against Biogen's Avonex.

You may also be interested in...



Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002

Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.

Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002

Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.

Serono Ovidrel

Filing for approval of the recombinant human chorionic gonadotropin is expected in both the U.S. and Europe by the end of the year, VP-Investor Relations & Scientific Affairs Andrew Galazka, MD, told the Warburg Dillon Read Conference Sept. 29. Phase III studies were completed in the second quarter (1"The Pink Sheet" Oct. 11, p. 22)

Related Content

UsernamePublicRestriction

Register

PS034944

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel